20.500.12556/DiRROS-24278 Ticagrelor is associated with increased rosuvastatin blood concentrations in patients who have had a myocardial infarction Aims: The primary objective of this study was to determine whether concomitant therapy with ticagrelor and rosuvastatin affects rosuvastatin plasma concentrations in patients receiving rosuvastatin 40 mg/day after myocardial infarction. Methods: We included 93 patients who had experienced a myocardial infarction and were receiving high-dose rosuvastatin 40 mg/day and a P2Y12 receptor antagonist, either ticagrelor, prasugrel or clopidogrel. We used liquid chromatography with tandem mass spectrometry to measure rosuvastatin plasma concentrations after liquid–liquid extraction. Results: Rosuvastatin plasma concentrations (9.7 ng/mL) were approximately twice as high in patients receiving ticagrelor therapy as in those receiving prasugrel (5.1 ng/mL, p<0.001) or clopidogrel (5.0 ng/mL, p=0.009), and ticagrelor was an independent factor influencing rosuvastatin concentrations. In addition, creatinine levels were associated with increased rosuvastatin concentrations (p=0.039). Conclusion: Our results suggest an important pharmacokinetic interaction between ticagrelor and rosuvastatin, leading to approximately two-fold higher rosuvastatin plasma concentrations in those receiving concomitant ticagrelor than in those receiving prasugrel or clopidogrel. The association is significant and independent of other potential factors influencing rosuvastatin levels, indicating its potential clinical relevance. clopidogrel drug interactions rosuvastatin pharmacokinetics ticagrelor concomitant therapy pharmacokinetic interaction myocardial infarction true false true Angleški jezik Ni določen Neznano 2025-11-24 14:27:50 2025-11-24 14:27:50 2025-11-25 04:09:24 0000-00-00 00:00:00 2025 0 0 Nasl z nasl. zaslona; Opis vira z dne 18. 8. 2025; Str. 565–571 no. 4 Vol. 64 2025 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 0000-00-00 616.1 1179-1926 10.1007/s40262-025-01489-1 245769987 RAZ_Dermota_Tjasa_2025.pdf RAZ_Dermota_Tjasa_2025.pdf 1 61942DE61D70B7CF17CF93196E7D5648 ddf5d274e00cddbd8607315ded7762608008be9a31511d0e4d51193b10d5c765 81522709-c939-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36168 https://link.springer.com/article/10.1007/s40262-025-01489-1 0 8b3fa4c7-c939-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36169 Univerzitetni klinični center Ljubljana 0 0 0